title: Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
abstract: BACKGROUND
  Novel therapies are needed for difficult-to-treat populations of patients with psoriasis.
  
  
  OBJECTIVE
  We sought to assess the efficacy and safety of the interleukin-17 Receptor A inhibitor brodalumab in patients with psoriasis with or without a self-reported history of psoriatic arthritis (PsA) and with or without a history of biologic use.
  
  
  METHODS
  Subset analyses of a phase II, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis were performed. Improvement from baseline in Psoriasis Area and Severity Index score of 75%, 90%, and 100% at week 12; static Physician Global Assessment (0/1) score; Dermatology Life Quality Index response; and Psoriasis Symptom Inventory response were evaluated within subgroups.
  
  
  RESULTS
  Efficacy and quality-of-life measures were generally similar between subgroups of patients with or without a history of PsA and with or without a history of biologic use across brodalumab doses and were significantly higher among patients who received brodalumab 140 mg every 2 weeks or 210 mg every 2 weeks versus placebo.
  
  
  CONCLUSIONS
  Differences between subgroups were not compared statistically, PsA was self-reported, only skin involvement/symptoms were reported, and reasons for discontinuation of prior biologic were not captured.
  
  
  CONCLUSIONS
  Brodalumab is efficacious in patients with psoriasis with or without a history of PsA or biologic use.
authors.affiliation: Probity Medical Research, Waterloo, Ontario, Canada.
authors.forename: Kim
authors.initials: K
authors.lastname: Papp
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
authors.affiliation: Probity Medical Research, Waterloo, Ontario, Canada; University of Connecticut School of Medicine, Farmington, Connecticut.
authors.forename: Bruce
authors.initials: B
authors.lastname: Strober
authors.affiliation: Amgen Inc, Thousand Oaks, California.
authors.forename: Greg
authors.initials: G
authors.lastname: Kricorian
authors.affiliation: Amgen Inc, Thousand Oaks, California.
authors.forename: Elizabeth H Z
authors.initials: EH
authors.lastname: Thompson
authors.affiliation: Amgen Inc, Thousand Oaks, California.
authors.forename: Cassandra E
authors.initials: CE
authors.lastname: Milmont
authors.affiliation: Amgen Inc, Thousand Oaks, California.
authors.forename: Ajay
authors.initials: A
authors.lastname: Nirula
authors.affiliation: Amgen Inc, Thousand Oaks, California. Electronic address: Klekotka@amgen.com.
authors.forename: Paul
authors.initials: P
authors.lastname: Klekotka
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571216:brodalumab
keywords: biologic; brodalumab; plaque psoriasis; psoriatic arthritis; quality of life; randomized controlled trial